key: cord-0892151-x11yb8ow
authors: Leung, Ann N.
title: COVID-19 Pandemic: The Road to Recovery
date: 2022-03-29
journal: Radiology
DOI: 10.1148/radiol.220488
sha: 0bfffc2fa3c99d058e84bb7e4b101734211fd786
doc_id: 892151
cord_uid: x11yb8ow

nan

This copy is for personal use only. To order printed copies, contact reprints@rsna.org with the most common symptoms being fatigue, shortness of breath, cough, anosmia, and insomnia (1) .

Persistent respiratory symptoms are believed, in part, to be due to structural lung damage that may result directly from SARS-CoV-2 infection or represent collateral injury from development of acute respiratory distress syndrome (ARDS) and use of mechanical ventilation.

In this issue of Radiology, Luger and colleagues (2) assessed the chest CT patterns and rate of improvement of pulmonary parenchymal disease at 2, 3, 6, and 12 months after initial onset of symptoms in 142 participants infected by SARS-CoV-2. COVID-19 severity in 91 participants who underwent 12month follow-up CT was categorized as mild (outpatient care) in 21% (n = 19); moderate (hospitalization without respiratory support) in 25% (n = 23); severe (hospitalization with supplemental oxygen) in 25% (n = 23); and critical (intensive care unit admission with non-invasive or mechanical ventilation) in 29% (n = 26).

On the first follow-up CT examination at 2 months, parenchymal abnormalities were identified in 76% (58/76) of participants. Ground-glass opacities, reticulation, and subpleural curvilinear lines were the most common findings and were present in 74%, 58%, and 36% of participants, respectively. Using a qualitative CT severity scale (CTSS) of disease ranging from 0 (normal) to 25 (all lobes involved), investigators found that the majority of participants showed gradual improvement in their parenchymal abnormalities. The rate of improvement was significantly faster in the early post-infectious period between 2 and 3 months as compared to the later period, between 6 and 12 months (p < 0.001). CT scans at 12 months showed persistent parenchymal abnormalities in 54% (49/91) of participants, with 34% (31/91) having minimal ground-glass and/or reticular opacities (CTSS score of ≤ 5) and the remaining 20% (18/91) having similar but more extensive findings in association with architectural distortion, bronchial dilatation, and/or microcystic change (CTSS score of > 5). Side-by-side comparison of 6-and 12-month CT scans showed no further change in parenchymal findings in 63% (31/49) of participants. 

The results of this study by Luger et al (2) are largely concordant with those of prior prospective longitudinal studies (3-7) that reported the temporal evolution of pulmonary abnormalities at CT in patients with COVID-19 extending to 12 months after acute infection. In these studies, the reported prevalence of CT parenchymal abnormalities at 3 months and 12 months ranged from 39% to 78% and 24% to 73%, respectively. This variability in the prevalence of persistent CT abnormalities likely reflects heterogeneity in the studies' enrolled patient populations with differences in underlying comorbidities, severity of COVID-19 disease, development of ARDS, and use of ventilation. In a study of 83 patients hospitalized for COVID-19 that excluded individuals with comorbidities, smoking history, or need for mechanical ventilation, persistent CT parenchymal abnormalities consisting primarily of ground-glass and reticular opacities were found in 24% of patients 12 months after discharge (5) . By comparison, in the study by Luger et al (2), 100% (13/13) of patients who developed ARDS had persistent CT findings at 12 months. Significant associations between older age (> 60 years) and severity of COVID-19 to persistence of CT findings at 12 months have been corroborated in other studies (3, 6) . The UK Interstitial Lung Disease-Long Covid Study (9) is a prospective, multicenter observational study that will enroll 12,000 patients with stratified severity of COVID-19; the study's primary objective is to determine the prevalence of interstitial lung disease at 12 months after infection and whether clinical severity correlates with CT findings. In the United States, the National Institutes of Health-sponsored Researching COVID to Enhance Recovery (RECOVER) initiative on PASC (10) will enroll 17,680 adults with COVID-19 and aggregate both retrospective and prospective data using an ambi-directional longitudinal study design. Radiography, CT, and MRI are embedded as integral components of patient assessment algorithms. The purpose of RECOVER is to characterize the spectrum of PASC symptoms and define its incidence, prevalence, and underlying mechanism with the study's overarching goal to better treat and prevent the development of PASC. I n p r e s s

Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review

Chest CT of lung injury one year after COVID-19 pneumonia: the CovILD study

Six-month follow-up chest CT findings after severe COVID-19 pneumonia

Fibrotic interstitial lung abnormalities at 1-year follow-up CT after severe COVID-19

3-Month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Chest CT patterns from diagnosis to 1 year of follow-up in patients with COVID-19

CT lung abnormalities after COVID-19 at 3 months and 1 year after hospital discharge

Longterm bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study